Abstract: The treatment landscape for B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia (WM), has been revolutionized by targeted therapies such as Bruton's Tyrosine Kinase inhibitors (BTKi) and BCL2 inhibitors. However, patients who become refractory to these treatments face a poor prognosis and limited therapeutic options, representing a significant unmet clinical need. Catadegbrutinib (BGB-16673) is a novel, orally administered, first-in-class proteolysis-targeting chimera (PROTAC) designed to degrade the BTK protein. By harnessing the ubiquitin-proteasome system, BGB-16673 eliminates both wild-type and mutant forms of BTK, effectively overcoming common resistance mutations (such as C481S and L528W) that render traditional covalent and non-covalent BTK inhibitors ineffective. Early clinical data from the CaDAnCe-101 trial demonstrate highly encouraging efficacy and a tolerable safety profile across multiple heavily pretreated B-cell malignancies. This review synthesizes the current literature on BGB-16673, detailing its pharmacological activity, molecular mechanism of action, structure-activity relationships, current limitations, and future clinical perspectives.
1. Introduction
B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Waldenström’s macroglobulinemia (WM), are driven by aberrant B-cell receptor (BCR) signaling [1]. Bruton's Tyrosine Kinase (BTK) is a critical cytoplasmic enzyme in this pathway, promoting malignant B-cell activation, proliferation, and survival [1].
The advent of covalent BTK inhibitors (cBTKi), such as ibrutinib, acalabrutinib, and zanubrutinib, and non-covalent BTK inhibitors (ncBTKi), such as pirtobrutinib, has significantly improved patient outcomes. However, the emergence of acquired resistance mutations in the BTK kinase domain remains a major clinical challenge. Patients who become "double refractory" to both a BTKi and a BCL2 inhibitor (like venetoclax) have very limited treatment options and a notably poor prognosis [1][3]. To address this unmet need, BTK protein degraders have emerged as a promising novel drug class. Catadegbrutinib (BGB-16673) is an orally administered BTK degrader currently under clinical investigation, showing potential to bypass traditional resistance mechanisms and provide durable clinical benefits in patients with relapsed or refractory (R/R) B-cell malignancies [1][2].
2. Pharmacological Activity
Preclinical pharmacokinetic studies of BGB-16673 in rats demonstrate an elimination half-life ranging from 7.2 to 10 hours. The compound is highly protein-bound and exhibits pH-dependent solubility. Interestingly, preclinical data suggest a disconnect between the pharmacokinetics and pharmacodynamics of the molecule; BGB-16673 exhibits a longer duration of response compared to inhibitors like ibrutinib and pirtobrutinib, providing a lasting therapeutic effect even after it has been eliminated from circulation [1].
Clinically, BGB-16673 is being evaluated in the Phase 1/2 CaDAnCe-101 dose-escalation and expansion study (NCT05006716) for patients with various R/R B-cell malignancies, including MZL, FL, MCL, CLL/SLL, WM, DLBCL, and Richter’s transformation (RT). Patients received oral doses ranging from 50 to 600 mg once daily. Pharmacodynamic data confirmed substantial and rapid reduction in BTK protein levels in peripheral blood and tumor tissue, even at the lowest 50 mg dose [1].
The clinical efficacy of BGB-16673 has been highly encouraging. In heavily pretreated patients with R/R CLL/SLL (median of 4 prior therapies), the overall response rate (ORR) was reported between 72% and 78%, including complete responses [1][2]. Responses were observed across high-risk patient groups, including those with unmutated IGHV, TP53 mutations, complex karyotypes, and prior BTK or PLCG2 mutations [1]. Furthermore, in patients with R/R WM, BGB-16673 demonstrated an impressive ORR of 90% [2].
The safety profile of BGB-16673 is comparable to other BTK-targeted agents and is generally well-tolerated. The most frequently reported adverse events include fatigue, contusion, anemia, diarrhea, and neutropenia. Notably, no instances of atrial fibrillation or hypertension—common adverse events associated with traditional BTK inhibitors—have been reported to date [1].
3. Molecular Mechanism of Action
BGB-16673 functions as a proteolysis-targeting chimera (PROTAC). Unlike traditional enzyme inhibitors that rely on "occupancy-driven" pharmacology (requiring continuous binding to inhibit the target), BGB-16673 utilizes "event-driven" pharmacology. A transient binding event is sufficient to trigger the irreversible destruction of the target protein [1].
The molecule is heterobifunctional, designed to bind simultaneously to the BTK protein and to an E3 ubiquitin ligase (specifically cereblon). The formation of this ternary complex brings the E3 ligase into close proximity with BTK, catalyzing the transfer of ubiquitin molecules to BTK. The polyubiquitinated BTK is subsequently recognized and degraded by the cell's proteasome [1][3]. Following the degradation of BTK, the BGB-16673 molecule is released intact and recycled to target additional BTK proteins, allowing for multiple rounds of catalytic degradation [1].
By completely removing the BTK protein from the cell, BGB-16673 eliminates not only its enzymatic kinase activity but also its structural scaffolding functions. This leads to a rapid, sustained, and robust inhibition of downstream BCR signaling cascades (such as the NF-κB and RAS-RAF-MEK-ERK pathways), thereby suppressing compensatory feedback activation and halting malignant B-cell growth [1].
4. Structure-Activity Relationship (SAR)
The structural design of BGB-16673 incorporates a BTK-binding moiety linked to a cereblon-recruiting E3 ubiquitin ligase-binding moiety [1][3]. This specific bifunctional architecture allows the drug to effectively target and degrade both wild-type (WT) BTK and various mutant forms of BTK that confer resistance to existing therapies [1].
Traditional cBTKis (like ibrutinib) bind covalently to the C481 residue of BTK; thus, the C481S mutation disrupts this bond and causes resistance. Non-covalent inhibitors (like pirtobrutinib) bypass this by binding reversibly, but they are susceptible to kinase-impaired gatekeeper mutations such as L528W and T474I, which alter the binding pocket or destabilize the protein structure [1][3]. Because BGB-16673 relies on degradation rather than sustained active-site inhibition, its structural moieties can successfully bind to these mutated BTK conformations (including C481S, L528W, and T474I) and induce their proteasomal clearance, restoring therapeutic efficacy in resistant disease states [1][3].
5. Current Limitations
Despite its promising profile, BGB-16673 faces several limitations and challenges:
Drug-Drug Interactions: BGB-16673 is metabolized by the Cytochrome P450 3A (CYP3A) enzyme. Consequently, co-administration with CYP3A inhibitors or inducers may significantly alter drug exposure. Additionally, because the compound has pH-dependent solubility, interactions with pH-lowering medications must be carefully considered in clinical practice [1].
Emergence of Novel Resistance Mutations: While BGB-16673 overcomes many known BTK mutations, selective pressure from the degrader can lead to new resistance mechanisms. A recent clinical case report identified the acquisition of a novel BTK mutation, A428D, in a patient treated with BGB-16673 who subsequently experienced disease progression. The A428D mutation is hypothesized to be kinase-impaired, though further functional studies are required to fully characterize how it evades PROTAC-mediated degradation [1][3].
Immature Long-Term Data: The clinical data for BGB-16673 are currently derived from early-phase trials with relatively short median follow-up periods (e.g., 4.6 months in the CLL/SLL cohort). Long-term durability of responses and the potential for late-emerging adverse events—which were historically observed with prolonged use of earlier BTK inhibitors—remain to be fully evaluated [1].
6. Future Perspectives
The compelling early efficacy of BGB-16673 in heavily pretreated, double-refractory CLL/SLL has led the FDA to grant it Fast Track designation, underscoring its potential to fill a critical void in the treatment landscape of B-cell malignancies [1].
Future clinical development will heavily focus on combination strategies to deepen responses, prolong survival, and prevent or delay the emergence of resistance mutations like A428D. A Phase 1b/2 trial (NCT06634589) is currently underway to evaluate BGB-16673 in combination with other targeted agents. Planned sub-studies include combining BGB-16673 with the BCL2 inhibitor sonrotoclax, as well as combining it with the cBTKi zanubrutinib, across a range of B-cell malignancies including WM, CLL, MCL, and MZL [1]. Furthermore, determining the optimal sequencing of BTK degraders relative to other novel agents and cellular therapies (such as CAR T-cell therapy and bispecific antibodies) will be a major focus of ongoing and future clinical research [1].
